These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24810608)

  • 1. Add-on effect of probucol in atherosclerotic, cholesterol-fed rabbits treated with atorvastatin.
    Keyamura Y; Nagano C; Kohashi M; Niimi M; Nozako M; Koyama T; Yasufuku R; Imaizumi A; Itabe H; Yoshikawa T
    PLoS One; 2014; 9(5):e96929. PubMed ID: 24810608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits.
    Niimi M; Keyamura Y; Nozako M; Koyama T; Kohashi M; Yasufuku R; Yoshikawa T; Fan J
    Lipids Health Dis; 2013 Nov; 12():166. PubMed ID: 24188322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demonstration of an add-on effect of probucol and cilostazol on the statin-induced anti-atherogenic effects.
    Wang Y; Bai L; Lin Y; Guan H; Zhu N; Chen Y; Li Y; Gao S; Zhao S; Fan J; Liu E
    Histol Histopathol; 2014 Dec; 29(12):1593-600. PubMed ID: 25078428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probucol suppresses macrophage infiltration and MMP expression in atherosclerotic plaques of WHHL rabbits.
    Li S; Liang J; Niimi M; Bilal Waqar A; Kang D; Koike T; Wang Y; Shiomi M; Fan J
    J Atheroscler Thromb; 2014; 21(7):648-58. PubMed ID: 24584175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of atorvastatin and/or probucol on recovery of atherosclerosis in high-fat-diet-fed apolipoprotein E-deficient mice.
    Guo X; Wang L; Xia X; Wang P; Li X
    Biomed Pharmacother; 2019 Jan; 109():1445-1453. PubMed ID: 30551396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous intake of oat bran and atorvastatin reduces their efficacy to lower lipid levels and atherosclerosis in LDLr-/- mice.
    Eussen SR; Rompelberg CJ; Andersson KE; Klungel OH; Hellstrand P; Oste R; van Kranen H; Garssen J
    Pharmacol Res; 2011 Jul; 64(1):36-43. PubMed ID: 21371558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
    Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
    J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of immunomodulatory drugs on plasma inflammatory markers in a rabbit model of atherosclerosis.
    Houssen ME; Haron MM; Metwally SS; Ibrahim TM
    J Physiol Biochem; 2011 Mar; 67(1):115-20. PubMed ID: 20960084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of probucol, aspirin and atorvastatin combination therapy upon atherosclerosis].
    Meng XP; Wang SX; Zhang JC; Li ZX; Geng L; Yin CY
    Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(28):1986-8. PubMed ID: 19950575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
    Krause BR; Newton RS
    Atherosclerosis; 1995 Oct; 117(2):237-44. PubMed ID: 8801869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice.
    Berbée JF; Wong MC; Wang Y; van der Hoorn JW; Khedoe PP; van Klinken JB; Mol IM; Hiemstra PS; Tsikas D; Romijn JA; Havekes LM; Princen HM; Rensen PC
    J Nutr Biochem; 2013 Aug; 24(8):1423-30. PubMed ID: 23337345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits.
    Wang Y; Bai L; Lin Y; Chen Y; Guan H; Zhu N; Li Y; Gao S; Sun L; Zhao S; Fan J; Liu E
    Lipids Health Dis; 2015 Jul; 14():82. PubMed ID: 26220196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.
    Kühnast S; van der Tuin SJ; van der Hoorn JW; van Klinken JB; Simic B; Pieterman E; Havekes LM; Landmesser U; Lüscher TF; Willems van Dijk K; Rensen PC; Jukema JW; Princen HM
    Eur Heart J; 2015 Jan; 36(1):39-48. PubMed ID: 25142968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined effect of atorvastatin and probucol on plasma cystatin C levels and severity of coronary lesion in patients with borderline coronary lesion.
    Ge CJ; Lü SZ; Feng LX; Huo Y; Song XT; Chen X; Meng K; Yuan F
    Chin Med J (Engl); 2012 Jul; 125(14):2472-6. PubMed ID: 22882924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet.
    Yoshikawa T; Mitani K; Kotosai K; Nozako M; Miyakoda G; Yabuuchi Y
    Horm Metab Res; 2008 Jul; 40(7):473-8. PubMed ID: 18404599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation.
    Sezer ED; Sozmen EY; Nart D; Onat T
    Vasc Health Risk Manag; 2011; 7():333-43. PubMed ID: 21731885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia.
    Kural BV; Orem C; Uydu HA; Alver A; Orem A
    Coron Artery Dis; 2004 Aug; 15(5):277-83. PubMed ID: 15238825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
    Verschuren L; Kleemann R; Offerman EH; Szalai AJ; Emeis SJ; Princen HM; Kooistra T
    Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):161-7. PubMed ID: 15514207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probucol up-regulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits.
    Hong SC; Zhao SP; Wu ZH
    J Cardiovasc Pharmacol; 2006 Jan; 47(1):77-81. PubMed ID: 16424789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis.
    Rathouska J; Vecerova L; Strasky Z; Slanarova M; Brcakova E; Mullerova Z; Andrys C; Micuda S; Nachtigal P
    Pharmacol Res; 2011 Jul; 64(1):53-9. PubMed ID: 21440631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.